降压药依普利酮安全吗

The new generation of selective aldosterone antagonist (eplerenone) was developed by Pfizer/Pharmacia under the trade name Inspra. It was first launched in the United States in 2002 and is used for the treatment of hypertension, heart failure and myocardial infarction. It has definite efficacy in treating hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated. Its outstanding advantage is that for severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of this product can significantly reduce blood pressure, especially the systolic blood pressure. For patients with severe heart failure and myocardial infarction, the combination of this product with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve the quality of life and reduce mortality.

(1) For the treatment of heart failure after acute myocardial infarction, combined with standard treatment drugs can reduce the total mortality in the treatment group by 15% (P=0.008);

(2) Eplerenone and enalapril are equally effective in reversing left ventricular hypertrophy and hypertension, with fewer cough side effects, and the combined effect is more obvious;

(3) There are few adverse reactions. Except for the adverse reactions of increased blood potassium, other adverse reactions are no different from the placebo group;

(4) There are almost no sex hormone-related side effects of spironolactone.

The FDA has approved (Inspra - Pfizer) for use in stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and congestive heart failure after acute myocardial infarction (MI) to improve survival. Eplerenone is the first aldosterone receptor blocker approved for this indication. The FDA's approval was based on the results of the EPHESUS (Eplerenone Efficacy and Survival Study in Heart Failure After Acute Myocardial Infarction) trial.